Care pathways in atopic dermatitis : a retrospective population-based cohort study

Autor: L. von Kobyletzki, N. Ballardini, D. Henrohn, M.P. Neary, G. Ortsäter, K. Geale, A. Rieem Dun, I. Lindberg, A. De Geer, P. Neregård, A. Cha, J.C. Cappelleri, W. Romero, J.P. Thyssen

Publikováno v: von Kobyletzki, L, Ballardini, N, Henrohn, D, Neary, M P, Ortsater, G, Geale, K, Rieem Dun, A, Lindberg, I, De Geer, A, Neregard, P, Cha, A, Cappelleri, J C, Romero, W & Thyssen, J P 2022, ' Care pathways in atopic dermatitis : a retrospective population-based cohort study ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 9, pp. 1456-1466 . https://doi.org/10.1111/jdv.18185

Background Atopic dermatitis (AD) is a complex disease with variations in severity and healthcare utilization. Examining patient pathways through analyses of longitudinal patient data provides an opportunity to describe real-world clinical patient ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598ccad227bd59e4da474323c2372615
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-196106

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry

Autor: Hendrik Schulze-Koops, Andrea Shapiro, Dimitrios A. Pappas, Kevin L. Winthrop, Harry Shi, David Gold, D. Henrohn, Gustavo Citera, Alina Onofrei, Carol A. Connell

Publikováno v: Annals of the Rheumatic Diseases

A randomised, open-label, blinded endpoint post-authorisation safety study (Study A3921133; NCT02092467; database not locked and subject to change) evaluated the safety of tofacitinib 5 mg and 10 mg twice daily (BID) versus tumour necrosis factor inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f929ad5e7d94ef5de38d1d0ecbbbbbf
http://europepmc.org/articles/PMC7788057

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB0248 INFLUENZA ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE TOFACITINIB CLINICAL PROGRAMME

Autor: M. Galindo-Izquierdo, Stanley Cohen, Andrea Shapiro, D. Henrohn, S. Marsal, A. Yndestad, Kevin L. Winthrop, Annette Diehl, H. Jo

Publikováno v: Annals of the Rheumatic Diseases. 80:1149-1150

Background:Patients (pts) with rheumatoid arthritis (RA) have an increased susceptibility to seasonal influenza and its complications.1 In light of the COVID-19 pandemic, there is a need to better understand acute respiratory viral RNA infections, su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8420d892d75dc86fa91a6944f0e74a9
https://doi.org/10.1136/annrheumdis-2021-eular.361

250 Direct healthcare cost of atopic dermatitis in the Swedish population

Autor: A. de Geer, A. Rieem Dun, Amy Cha, I. Lindberg, Maureen P Neary, G. Ortsäter, L. Von Kobyletzki, William Romero, Joseph C. Cappelleri, D. Henrohn, Kirk Geale, P. Neregard, Jacob P. Thyssen, A. Metsini

Publikováno v: Journal of Investigative Dermatology. 141:S45

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ce9652e8deafc900fb626309a439299
https://doi.org/10.1016/j.jid.2021.02.272